Impact of antithymocyte globulin usage and risk stratification for posttransplant lymphoproliferative disorders in aplastic anemia patients after allogeneic hematopoietic cell transplantation
- 10 February 2024
- journal article
- letter
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 59 (5) , 688-691
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Risk Factors for the Incidence of and the Mortality due to Post-Transplant Lymphoproliferative Disorder after Hematopoietic Cell TransplantationTransplantation and Cellular Therapy, 2022
- Risk Factors and Predictive Scoring System For Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell TransplantationTransplantation and Cellular Therapy, 2019
- Post-Transplantation Lymphoproliferative Disorders in AdultsNew England Journal of Medicine, 2018
- Risk factors for post‐transplant lymphoproliferative disorder after Thymoglobulin‐conditioned hematopoietic cell transplantationClinical Transplantation, 2017
- Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantationHaematologica, 2013
- Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantationBlood, 2009
- Prior immunosuppressive therapy with antithymocyte globulin increases the risk of EBV-related lymphoproliferative disorder following allo-SCT for acquired aplastic anaemiaBone Marrow Transplantation, 2008
- Poor outcome in post transplant lymphoproliferative disorder with pulmonary involvement after allogeneic hematopoietic SCT: 13 years' experience in a single instituteBone Marrow Transplantation, 2008
- Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study.1999
- B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcomeBone Marrow Transplantation, 1999